These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22966017)

  • 1. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
    Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
    Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
    Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
    Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
    Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
    Chen L; Monti S; Juszczynski P; Ouyang J; Chapuy B; Neuberg D; Doench JG; Bogusz AM; Habermann TM; Dogan A; Witzig TE; Kutok JL; Rodig SJ; Golub T; Shipp MA
    Cancer Cell; 2013 Jun; 23(6):826-38. PubMed ID: 23764004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell receptor signaling down-regulates forkhead box transcription factor class O 1 mRNA expression via phosphatidylinositol 3-kinase and Bruton's tyrosine kinase.
    Hinman RM; Bushanam JN; Nichols WA; Satterthwaite AB
    J Immunol; 2007 Jan; 178(2):740-7. PubMed ID: 17202334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
    Craxton A; Jiang A; Kurosaki T; Clark EA
    J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
    Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
    Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
    Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
    Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
    Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
    Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
    Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Processing of CD74 by the Intramembrane Protease SPPL2a Is Critical for B Cell Receptor Signaling in Transitional B Cells.
    Hüttl S; Kläsener K; Schweizer M; Schneppenheim J; Oberg HH; Kabelitz D; Reth M; Saftig P; Schröder B
    J Immunol; 2015 Aug; 195(4):1548-63. PubMed ID: 26157172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.
    Bogusz AM; Kovach AE; Le LP; Feng D; Baxter RH; Sohani AR
    PLoS One; 2017; 12(2):e0172364. PubMed ID: 28212447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
    Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
    Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
    Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function.
    Kurosaki T; Kurosaki M
    J Biol Chem; 1997 Jun; 272(25):15595-8. PubMed ID: 9188445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
    Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
    Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.